74 related articles for article (PubMed ID: 21475812)
1. Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma.
Funao K; Matsuyama M; Kawahito Y; Sano H; Chargui J; Touraine JL; Nakatani T; Yoshimura R
Mol Med Rep; 2009; 2(2):193-8. PubMed ID: 21475812
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan is a potent target for prevention and treatment in human prostate cancer.
Funao K; Matsuyama M; Kawahito Y; Sano H; Chargui J; Touraine JL; Nakatani T; Yoshimura R
Oncol Rep; 2008 Aug; 20(2):295-300. PubMed ID: 18636189
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan inhibits human urological cancer cell growth through early apoptosis.
Matsuyama M; Funao K; Kuratsukuri K; Tanaka T; Kawahito Y; Sano H; Chargui J; Touraine JL; Yoshimura N; Yoshimura R
Exp Ther Med; 2010 Mar; 1(2):301-306. PubMed ID: 22993542
[TBL] [Abstract][Full Text] [Related]
4. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells.
Yoshimura R; Matsuyama M; Hase T; Tsuchida K; Kuratsukuri K; Kawahito Y; Sano H; Segawa Y; Nakatani T
Int J Mol Med; 2003 Dec; 12(6):861-5. PubMed ID: 14612958
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
6. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action.
Ishiguro H; Ishiguro Y; Kubota Y; Uemura H
Prostate; 2007 Jun; 67(9):924-32. PubMed ID: 17440964
[TBL] [Abstract][Full Text] [Related]
7. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Uchida K; Hisasue S; Kitamura H; Itoh N; Tsukamoto T
Urology; 2005 Mar; 65(3):594-9. PubMed ID: 15780399
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
Hattori N; Yamada A; Nakatsuji S; Matsuda T; Nishiyama N; Shimatsu A
J Mol Endocrinol; 2022 May; 69(1):259-268. PubMed ID: 35354667
[TBL] [Abstract][Full Text] [Related]
9. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
Marshall TG; Lee RE; Marshall FE
Theor Biol Med Model; 2006 Jan; 3():1. PubMed ID: 16403216
[TBL] [Abstract][Full Text] [Related]
10. The cysteinylLT1 receptor in human renal cell carcinoma.
Funao K; Matsuyama M; Naganuma T; Kawahito Y; Sano H; Nakatani T; Yoshimura R
Mol Med Rep; 2008; 1(2):185-9. PubMed ID: 21479395
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan-Induced Cytotoxicity via G
Tsujiya Y; Hasegawa A; Yamamori M; Okamura N
Biol Pharm Bull; 2021; 44(12):1878-1885. PubMed ID: 34853271
[TBL] [Abstract][Full Text] [Related]
12. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
14. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
[TBL] [Abstract][Full Text] [Related]
15. Increase of human prostate cancer cell (DU145) apoptosis by telmisartan through PPAR-delta pathway.
Wu TT; Niu HS; Chen LJ; Cheng JT; Tong YC
Eur J Pharmacol; 2016 Mar; 775():35-42. PubMed ID: 26852954
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between peroxisome proliferator activator-receptor (PPAR) and urological cancer].
Yoshimura R; Nakatani T
Nihon Rinsho; 2005 Apr; 63(4):672-8. PubMed ID: 15828236
[TBL] [Abstract][Full Text] [Related]
17. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
18. Lipoxygenase inhibitors prevent urological cancer cell growth.
Matsuyama M; Yoshimura R; Tsuchida K; Takemoto Y; Segawa Y; Shinnka T; Kawahito Y; Sano H; Nakatani T
Int J Mol Med; 2004 May; 13(5):665-8. PubMed ID: 15067367
[TBL] [Abstract][Full Text] [Related]
19. Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor.
Yoshimura R; Inoue K; Kawahito Y; Mitsuhashi M; Tsuchida K; Matsuyama M; Sano H; Nakatani T
Int J Mol Med; 2004 Jan; 13(1):41-6. PubMed ID: 14654968
[TBL] [Abstract][Full Text] [Related]
20. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma.
Takashima T; Fujiwara Y; Hamaguchi M; Sasaki E; Tominaga K; Watanabe T; Oshitani N; Higuchi K; Arakawa T
Oncol Rep; 2005 Apr; 13(4):601-6. PubMed ID: 15756430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
